Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Asthma Severity in Women: The Influence of Training and Menopause (ATOM)

17 czerwca 2021 zaktualizowane przez: Vibeke Backer, Rigshospitalet, Denmark

The ATOM Study: Asthma Severity in Women: The Influence of Training and Menopause

Introduction: Late-onset asthma in women is characterized by poor disease control and reduced quality of life despite intensive treatment with inhaled steroid and beta2-agonist. The condition is further worsened at menopause due to the loss of estrogen leading to increased asthma exacerbation frequency, increased airway inflammation and decreased lung function. Exercise training may increase disease control of asthma patients, but to what extent the same effect is seen in postmenopausal women with late-onset asthma is unknown. These asthma patients represent a phenotype that is characterized by low eosinophilic airway inflammation, severe symptoms, moderate obesity and poor response to conventional medicine. Thus, our hypothesis is that regular physical exercise is especially associated with an improvement in asthma control in this phenotype. The aim of this project is to test this hypothesis and to assess whether an improvement is associated with reduced local and systemic inflammation, change in heart function, lung function and/or body composition.

Study design: 40 postmenopausal women with late-onset asthma are recruited via the outpatient clinic at the Respiratory Department at Bispebjerg Hospital and through advertisement. The participants are randomized 1:1 into two groups. One group performs supervised exercise training (spinning) three times per week for 12 weeks while the other group is a control group. Before and after the intervention asthma control, local and systemic inflammation, heart function and body composition is measured.

Results: Analysis will be performed to detect changes within and between the groups before and after intervention. Primary outcome is change in ACQ (Asthma Control Questionnaire). Local and systemic inflammation is measured by changes in bronchial challenge to methacholine, sputum cell count and blood tests. Furthermore, secondary outcomes include change in heart function measured by stress-echocardiography and change in body composition measured by Dual-energy X-ray absorptiometry (DEXA).

Conclusion: There are to date no prospective studies that can support recommendations containing asthma rehabilitation with supervised regular physical activity for postmenopausal women. Thus, this study will provide novel understanding of the importance of physical activity in a chronic disease such as asthma.

Przegląd badań

Status

Zakończony

Interwencja / Leczenie

Szczegółowy opis

Overall study design

The study is a single-blinded randomized controlled intervention study. Forty postmenopausal women with late-onset asthma (>16 years at debut) are recruited from the asthma outpatient-clinic at Bispebjerg Hospital or other hospital/practitioner in the region and/or by advertisement. The participants are block-randomized into two groups of 20, where one group is control and the other undergoes a period of regular exercise training. The investigators will be blinded and will not know whether the subjects have trained or not.

Detailed study design

Participants allocated to the exercise training group undergo a training intervention consisting of 45 minutes of intermittent high intensity aerobic spinning training three times per week for 12 weeks. Participants allocated to the control group will continue usual care without training. No changes to current treatment will be made by the investigators on any of the groups.

The training will consist of short periods of high intensity intervals where subjects reach above 80% of maximal oxygen consumption. Spinning sessions will be fully supervised by trained instructors with a bachelor of sports and science or bachelor of medicine and conducted in the Department of Nutrition, Exercise and Sports, University of Copenhagen. Subjects will wear heart rate monitors to ensure adherence to the training protocol. Within two weeks, before and after the intervention, participants from both groups undergo 3 days of testing.

To ensure equal compliance with asthma medication both groups will receive daily electronic reminders. Once a week, all participants will be asked about their compliance to their medication.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

12

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

      • Copenhagen, Dania, 2400
        • Respiratory research unit, Bispebjerg University Hospital

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

45 lat do 75 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Kobieta

Opis

Inclusion Criteria:

  • Late onset asthma (Debut ≥ 16 years of age)
  • ACQ ≥ 1.25
  • Daily treatment for asthma (GINA 2 and above)
  • Age 45 - 75
  • Postmenopausal defined as no menstruation for 6 months, Serum Follicle stimulating hormone >20 International Units per Liter and P-Estradiol nmol/L <0.09
  • BMI 25 - 35
  • Positive bronchial challenge to methacholine, mannitol or positive reversibility to beta2-agonist now or historically
  • Untrained (no participation in vigorous exercise for more than 1 hour per week during the last 2 months)
  • Capable of exercising on a bike

Exclusion Criteria:

  • Unable to speak and understand Danish or English.
  • Current or former smokers (>6 months cessation) with >20 years of daily smoking with 20 cigarettes per day.
  • Other respiratory disease of clinical significance
  • Cardiovascular: Unstable ischemic heart disease, myocardial infarction within the last 12 months, symptomatic heart failure (EF <40%), symptomatic heart arrhythmia (documented with ECG), uncontrolled hypertension (>155/100)
  • Any disorder that is not stable and in the opinion of the investigator could affect the safety of the subject throughout the study
  • Subjects, who by investigators determination, will not be able to adhere to study protocol

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Podwójnie

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Aerobic exercise intervention
Aerobic exercise by high intensity interval training, 3 times per week for 12 weeks
High Intensity Interval Training (HIIT)
Brak interwencji: Control group
No intervention for 12 weeks

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Asthma control - Asthma Control Questionnaire (ACQ)
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention
Changes in Asthma Control Questionnaire (ACQ) 7-point scale (0=no impairment, 6= maximum impairment for symptoms and rescue use)
-21 to 0 days before intervention and 0 to 14 days post intervention

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Heart Rate Variability
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in:

- Heart rate variability

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart rhytm
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in:

- Heart rhythm

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart Rate
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in:

- electrocardiography

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Strain
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Measured by stress-echocardiography

- Strain

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Ejection fraction
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Measured by stress-echocardiography

- Ejection fraction

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Tricuspid annular plane systolic excursion
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Measured by stress-echocardiography

- Tricuspid annular plane systolic excursion

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Right ventricular function
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Measured by stress-echocardiography

- Right ventricular function

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Pulmonary pressure
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Measured by stress-echocardiography

- Pulmonary pressure

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Lung covered cor
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Measured by stress-echocardiography

- Lung covered cor

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Blood pressure
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention
Blood pressure
-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Cardiac output
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention
Cardiac output
-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Stroke volume
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention
Stroke volume
-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Total peripheral resistance
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention
Total peripheral resistance
-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation - Leukocytes + differential cell count count
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Leukocytes + differential cell count count

-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation - Interleukin 6
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Interleukin 6

-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation - Interleukin 8
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Interleukin 8

-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Other interleukins

-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation - Tumor Necrosis Factor alpha
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Tumor Necrosis Factor alpha

-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation - Total immunoglobulin E, Specific immunoglobulin E
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

  • Total immunoglobulin E
  • Specific immunoglobulin E
-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation - high sensitivity c reactive protein
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- high sensitivity c reactive protein

-21 to 0 days before intervention and 0 to 14 days post intervention
Local airway inflammation - Sputum cell count
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Sputum cell count

-21 to 0 days before intervention and 0 to 14 days post intervention
Local airway inflammation - Fraction of exhaled nitric oxide
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Fraction of exhaled nitric oxide

-21 to 0 days before intervention and 0 to 14 days post intervention
Local airway inflammation - Hyperreactivity to inhaled methacholine
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Hyperreactivity to inhaled methacholine

-21 to 0 days before intervention and 0 to 14 days post intervention
Body Composition
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Total body fat

-21 to 0 days before intervention and 0 to 14 days post intervention
Body Composition
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Lean body mass

-21 to 0 days before intervention and 0 to 14 days post intervention
Body Composition
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Muscle mass

-21 to 0 days before intervention and 0 to 14 days post intervention
Body Composition
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Weight

-21 to 0 days before intervention and 0 to 14 days post intervention
Microbiome
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention
Changes in the microbiota in sputum, oral cavity and nasal cavity before and after the training intervention
-21 to 0 days before intervention and 0 to 14 days post intervention
Compliance - Foster score
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Change in

- Foster score Answers describe last weeks medicine use. Answers range form 0/7 - 7/7 with low values being worse.

-21 to 0 days before intervention and 0 to 14 days post intervention
Other asthma related questionnaires - Nijmegen questionnaire
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Nijmegen questionnaire Values range from 0-64 and values below 20 are considered normal.

-21 to 0 days before intervention and 0 to 14 days post intervention
Other asthma related questionnaires - Mini Asthma Quality of Life Questionnaire (miniAQLQ)
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Mini Asthma Quality of Life Questionnaire (miniAQLQ) 7-point Likert scale (7 = not impaired at all - 1 = severely impaired).

-21 to 0 days before intervention and 0 to 14 days post intervention
Other asthma related questionnaires - Hospital Anxiety and Depression Scale (HADS) 2 items with 7 questions regarding anxiety and depression. (0 = no sign of depression/anxiety, 21 = maximal signs of anxiety/depression)
Ramy czasowe: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Hospital Anxiety and Depression Scale (HADS)

-21 to 0 days before intervention and 0 to 14 days post intervention

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Vibeke Backer, Physician, Respiratory Research Unit, Bispebjerg Hospital

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

12 lutego 2019

Zakończenie podstawowe (Rzeczywisty)

1 maja 2021

Ukończenie studiów (Rzeczywisty)

1 maja 2021

Daty rejestracji na studia

Pierwszy przesłany

9 listopada 2018

Pierwszy przesłany, który spełnia kryteria kontroli jakości

19 listopada 2018

Pierwszy wysłany (Rzeczywisty)

20 listopada 2018

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

23 czerwca 2021

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

17 czerwca 2021

Ostatnia weryfikacja

1 czerwca 2021

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

Data that support the results of this study will be made available immediately, with no end date, after deidentification and upon reasonable request.

Ramy czasowe udostępniania IPD

Immediately after publication with no end date.

Kryteria dostępu do udostępniania IPD

Data will be made available upon reasonable request to achieve the aims of the reasonable request.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj